<?xml version="1.0" encoding="UTF-8"?>
<p id="Par55">Drugs affecting such targets and their status for SARS-CoV-2 are listed below. The main candidates as inhibitors of 3CLpro include lopinavir, ritonavir, darunavir, cobicistat, and ASC09F (phase III, in combination with oseltamivir, for SARS-CoV-2).
 <sup>
  <xref ref-type="bibr" rid="CR152">152</xref>
 </sup> Candidates as inhibitors of PLpro include thiopurine analogs, compound 6 (preclinical), and remdesivir (phase III for MARS-CoV).
 <sup>
  <xref ref-type="bibr" rid="CR121">121</xref>,
  <xref ref-type="bibr" rid="CR153">153</xref>
 </sup> Favipiravir, ribavirin (randomized trial for SARS-CoV-2), and remdesivir are among the candidate inhibitors of RdRp.
 <sup>
  <xref ref-type="bibr" rid="CR118">118</xref>
 </sup> Previously, compounds that may interfere with ATPase and helicase activities were reported (before COVID-19), such as bananins, 5-hydroxychromone derivatives, and triazole derivatives (preclinical).
 <sup>
  <xref ref-type="bibr" rid="CR34">34</xref>,
  <xref ref-type="bibr" rid="CR78">78</xref>
 </sup> Candidates that may suppress viral entry by targeting the S protein include peptide P9 and Î±-helical lipopeptides (preclinical),
 <sup>
  <xref ref-type="bibr" rid="CR154">154</xref>
 </sup> and those targeting the S2 subunit of the S protein mainly include HR1P, HR1M, HR1L, HR2L, HR2P, and HR2L (preclinical).
 <sup>
  <xref ref-type="bibr" rid="CR155">155</xref>
 </sup>
</p>
